Quarterly Pricing Pulse — Q3 2026

AbbVie filed multiple material events in Q3 (July 6, July 31, August 5), signaling ongoing adjustments to its Botox/Juvéderm + Allē loyalty ecosystem. The pattern is clear: AbbVie is doubling down on rebate-stacking and patient loyalty capture to defend market share against Evolus's aggressive Jeuveau pricing. For practice owners, this means:

• Allē enrollment and redemption rates are likely climbing—patients are learning to expect rebates, which can compress your effective price per unit
• Volume thresholds and tiered rebates are the new battleground; practices hitting higher volumes may see better terms, but smaller practices may not
• Margin erosion is real: if you're not actively modeling rebate impact on your per-unit cost, you're flying blind

Action: Audit your Q3 Allē rebate redemption data. Calculate your true net revenue per Botox/Juvéderm unit after rebates. If margins have slipped >5%, consider whether volume growth or price increases can offset the loss.

Evolus filed four material events in Q3 (June 12, July 8, August 4, August 5), all tied to Jeuveau ('Newtox') and Evolus Rewards. Evolus is explicitly targeting medspas with aggressive pricing and rebate programs—a direct challenge to AbbVie's dominance. Clinical trials on Botox (AbbVie) and a Merz botulinum toxin (NT 201) also completed or are recruiting, suggesting the category remains competitive and innovation-focused.

• Jeuveau is gaining traction in medspa channels because Evolus's rebate structure is often more favorable for smaller practices than AbbVie's volume-tiered model
• Expect Jeuveau pricing to remain aggressive through Q4 as Evolus fights for market share
• Switching costs are low: if your patients don't perceive a clinical difference, rebate economics may drive your choice

Action: Request updated pricing and rebate schedules from both AbbVie and Evolus. Run a side-by-side margin analysis for a typical month of Botox/Jeuveau volume. If Jeuveau's net margin is >10% better, pilot a small patient cohort to test satisfaction and retention.

Hims & Hers filed six material events in Q3 (June 2, June 15, July 1, July 17, August 10), and Eli Lilly filed one (August 5). The signal: GLP-1 supply, pricing, and regulatory rules are in flux, and telehealth platforms are capturing a growing share of the cash-pay weight-loss market. Viking Therapeutics also filed on its next-gen GLP-1 pipeline (VK2735), hinting at future supply and pricing competition.

• Compounding rules and supply constraints are top-of-mind for Eli Lilly and the telehealth players; if you're offering compounded GLP-1, regulatory clarity is still pending
• Hims & Hers is a direct competitor for your cash-pay GLP-1 patients; their scale and brand recognition make them a formidable threat
• Margins on GLP-1 are under pressure as supply normalizes and telehealth platforms commoditize the offering

Action: If you offer GLP-1, review your pricing against Hims & Hers and other telehealth competitors. Assess whether your clinical value-add (in-person follow-up, combination treatments, aesthetics integration) justifies a premium. If not, consider whether GLP-1 is a loss-leader to drive other revenue or a core profit center you need to defend.

Multiple filler trials advanced in Q3—Galderma, Hallura, Helios, and others—signaling ongoing innovation and competitive positioning. Galderma completed two trials (décolletage wrinkles, chin augmentation), and several new fillers are in early recruitment. However, SEC filings from filler makers were sparse, suggesting pricing and rebate moves are less dramatic than in botulinum toxin.

• Filler category is less commoditized than Botox, so rebate wars are less intense (for now)
• Clinical differentiation still matters: new fillers targeting specific indications (décolletage, chin) may command premium pricing
• Supply chain remains stable; Henry Schein filed on distribution (August 4), but no major disruptions reported

Action: Monitor filler trial outcomes and FDA approvals. If new fillers enter your market, evaluate whether their clinical claims justify higher pricing or if they'll compress margins. Maintain relationships with 2–3 filler suppliers to negotiate volume discounts if pricing pressure emerges.

Apyx Medical (Renuvion) filed five material events in Q3, and Bausch Health (Solta) filed two, signaling active device-category engagement. HydraFacial (The Beauty Health Company) filed three events, reflecting strong consumable/device demand in the facial category. However, Bausch Health's Solta filings hint at potential spin-off or M&A activity, which could affect pricing, support, and consumable availability.

• Renuvion (helium-plasma) adoption is steady; multiple filings suggest ongoing clinical and safety work, a positive signal for long-term support
• HydraFacial consumables remain a reliable revenue stream for medspas; demand signals are strong
• Solta's future is uncertain; if Bausch divests or restructures, pricing and support could shift

Action: If you use Solta devices (Thermage, Fraxel, Clear+Brilliant), monitor Bausch Health news for M&A announcements. Ensure you have consumable inventory and service contracts locked in before any ownership change. For Renuvion and HydraFacial, current pricing and support appear stable; no urgent action needed.

e.l.f. Beauty filed a material event (August 5), a proxy for consumer aesthetic and beauty spending. The broader context: discretionary beauty spend is under pressure in some segments, but premium/professional services (like medspas) have shown resilience. GLP-1 adoption is also shifting consumer priorities—weight loss and body contouring may be competing for the same cash-pay budget.

• Consumer beauty spend is bifurcating: mass-market brands are under pressure, but premium services (injectables, professional facials) remain resilient
• GLP-1 adoption may cannibalize some aesthetic spending as patients prioritize weight loss; body-contouring and cellulite treatments could see increased demand as a result
• Pricing power for premium treatments remains intact, but volume may soften if discretionary income tightens

Action: Review your patient acquisition cost and lifetime value by service category. If GLP-1 or weight-loss services are growing, ensure you're capturing the downstream body-contouring and cellulite-treatment demand. If consumer spend is softening, focus on retention and upsell rather than aggressive new-patient acquisition.